The case for & against
Bull & Bear analysis
Allurion Technologies Inc. (NASDAQ: ALUR) specializes in developing innovative obesity management solutions, prominently featuring its Allurion balloon and a suite of AI-driven digital health applications known as the Virtual Care Suite (VCS). The company is positioned to disrupt traditional obesity therapies by combining its offerings with GLP-1 medications; this positions Allurion at the forefront of evolving health initiatives aimed at combating the obesity crisis. With the backdrop of a dynamic regulatory environment and a focus on developing non-surgical weight loss methods, Allurion aims to capture substantial market share through its clinically validated products.
Bull says
- ↑Allurion balloon combined with GLP-1 therapy may set new care standard
- ↑Operating expenses down 45% YoY; 50% further cuts planned in 2025
- ↑Clinics using combo therapy rose 20% in Middle East, early recovery
- ↑Analyst consensus PT $4.52 implies ~212% upside from $1.45
- ↑Five-point plan targets PMA completion, commercialization, AI-driven VCS
- ↑0.76% dividend yield and positive analyst revisions signal growing interest
Bear says
- ↓Q3 revenue $2.7M down 50% YoY; France sales suspension underscores regulatory risk
- ↓Q3 operating loss $9.6M vs $12.3M prior; cash reserves $6.1M risk extended runway
- ↓Shift from DTC to B2B2C may disrupt sales if execution misfires
- ↓Success reliant on GLP-1 adoption; any market fluctuation poses threat
- ↓Negative profitability factors and high volatility indicate unstable returns
- ↓Pending PMA approval and regulatory hurdles could delay U.S. market entry
Earnings Call · Q3 2024 · Mgmt. Guidance
Transcript signals
Bull points
- In the third quarter, we worked with ANSM on a remediation plan, which we completed in October. we remain optimistic about resuming commercialization in France as soon as possible.
- One of the most exciting things I have to announce today for the first time is that we have seen significant growth in recurring revenue from our AI-native platform, the Allurion Virtual Care Suite, or VCS, for a third quarter in a row.
- We believe that the Illurion balloon can be a highly attractive therapeutic alternative for the millions of people in the United States who are trying GLP-1s, churning off, and then regaining their weight.
Bear points
- the suspension of the Allurion balloon in France, macro headwinds in certain markets, and the launch of compounded and, in some cases, counterfeit GLP-1 drugs in the UK.
- As a result, we expect 2024 revenue to be in the range of $30 to $35 million and procedure volume to be flat compared to 2023.
- As a result, we expect 2024 revenue to be in the range of $30 to $35 million and procedure volume to be flat compared to 2023.